Preparation of Chitosan/Alginate-ellagic Acid Sustained-release Microspheres and their Inhibition of Preadipocyte Adipogenic Differentiation

Ding, Chengshi; Haidan, Bi; Wang, Deya; Kang, Meiling; Tian, Zhongjing; Zhang, Yingxia; Wang, Hongkai; Zhu, Tianshun; Ma, Jun

doi:10.2174/1389201020666190809110511

Cited by 9 publications

(5 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A recent study by Ding et al focused on the preparation of EA microspheres based on CS and sodium alginate as coating materials [78]. CS-alginate microparticles (MPs) were prepared by ionotropic gelation.…”

Section: Chitosan Micro/nanospheresmentioning

confidence: 99%

Formulation Strategies to Improve Oral Bioavailability of Ellagic Acid

et al. 2020

View full text Add to dashboard Cite

Ellagic acid, a polyphenolic compound present in fruit and berries, has recently been the object of extensive research for its antioxidant activity, which might be useful for the prevention and treatment of cancer, cardiovascular pathologies, and neurodegenerative disorders. Its protective role justifies numerous attempts to include it in functional food preparations and in dietary supplements, and not only to limit the unpleasant collateral effects of chemotherapy. However, ellagic acid use as a chemopreventive agent has been debated because of its poor bioavailability associated with low solubility, limited permeability, first pass effect, and interindividual variability in gut microbial transformations. To overcome these drawbacks, various strategies for oral administration including solid dispersions, micro and nanoparticles, inclusion complexes, self-emulsifying systems, and polymorphs were proposed. Here, we listed an updated description of pursued micro and nanotechnological approaches focusing on the fabrication processes and the features of the obtained products, as well as on the positive results yielded by in vitro and in vivo studies in comparison to the raw material. The micro and nanosized formulations here described might be exploited for pharmaceutical delivery of this active, as well as for the production of nutritional supplements or for the enrichment of novel foods.

show abstract

Section: Chitosan Micro/nanospheresmentioning

confidence: 99%

Formulation Strategies to Improve Oral Bioavailability of Ellagic Acid

et al. 2020

View full text Add to dashboard Cite

show abstract

“…The obtained materials showed antioxidant activity [120]. Additionally, ellagic acid was used as a chitosan/sodium alginate modifier [146]. It was also added to a starch-based film as an active compound [147].…”

Section: Phenolic Acids With Other Natural Polymersmentioning

confidence: 99%

Collagen-Based Materials Modified by Phenolic Acids—A Review

Kaczmarek

Mazur

2020

Materials

View full text Add to dashboard Cite

Collagen-based biomaterials constitute one of the most widely studied types of materials for biomedical applications. Low thermal and mechanical parameters are the main disadvantages of such structures. Moreover, they present low stability in the case of degradation by collagenase. To improve the properties of collagen-based materials, different types of cross-linkers have been researched. In recent years, phenolic acids have been studied as collagen modifiers. Mainly, tannic acid has been tested for collagen modification as it interacts with a polymeric chain by strong hydrogen bonds. When compared to pure collagen, such complexes show both antimicrobial activity and improved physicochemical properties. Less research reporting on other phenolic acids has been published. This review is a summary of the present knowledge about phenolic acids (e.g., tannic, ferulic, gallic, and caffeic acid) application as collagen cross-linkers. The studies concerning collagen-based materials with phenolic acids are summarized and discussed.

show abstract

“…Growing evidence demonstrates that this strategy allows the delivery of higher local concentrations of drugs, which can enhance their therapeutic efficacy 73,74 . In this sense, novel drug-delivery systems that overcome the low EA solubility and bioavailability (i.e., biocompatible polymers-based nanoparticles/ microcapsules/ biofilms/ micelles) are being tested in vitro and in vivo [75][76][77][78][79] . In summary, we found that EA affects cell cycle progression of endometrial stromal cells through the arrest at G2/M phase.…”

Section: Discussionmentioning

confidence: 99%